874518-45-3Relevant articles and documents
In silico design and synthesis of N-arylalkanyl 2-naphthamides as a new class of non-purine xanthine oxidase inhibitors
Ho, Sheau Ling,Lin, Ching-Ting,Lee, Shoei-Sheng
, p. 789 - 801 (2021/01/12)
A series of N-arylalkanyl 2-naphthamides (Xa~e), which were predicted from virtual molecular docking on a built xanthine oxidase template as potential inhibitors, were synthesized. Their inhibitory activity against xanthine oxidase was assayed. Among these prepared, compounds Xb (IC50 13.6?μM), Xc (IC50 13.1?μM), and Xd (IC50 12.5?μM) showed comparable inhibitory activity to allopurinol (IC50 22.1?μM). The in vitro assay result correlated well with molecular docking scores, ΔG?=??16.99, ?17.66, and ?17.13 Kcal/mol, respectively. On the potassium oxonate-induced hyperuricemic mice model, oral administration of Xc-Ac (40 mg/ Kg), the per-O-acetylated Xc, could reduce the blood uric acid level by 60% in comparison to the normal control group and is statistically significant (p .01) while compared with the hyperuricemic mice group.
New potent and selective polyfluoroalkyl ketone inhibitors of GVIA calcium-independent phospholipase A2
Magrioti, Victoria,Nikolaou, Aikaterini,Smyrniotou, Annetta,Shah, Ishita,Constantinou-Kokotou, Violetta,Dennis, Edward A.,Kokotos, George
supporting information, p. 5823 - 5829 (2013/09/12)
Group VIA calcium-independent phospholipase A2 (GVIA iPLA 2) has recently emerged as an important pharmaceutical target. Selective and potent GVIA iPLA2 inhibitors can be used to study its role in various neurological diso
